Short Interest in Universe Pharmaceuticals INC (NASDAQ:UPC) Decreases By 58.7%

Universe Pharmaceuticals INC (NASDAQ:UPC) was the target of a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 6,382 shares, a drop of 58.7% from the July 15th total of 15,446 shares. Based on an average daily trading volume, of 1,046,971 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.3% of the shares of the company are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings raised Universe Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Universe Pharmaceuticals Stock Down 3.7%

UPC opened at $5.65 on Friday. The company has a 50 day moving average of $4.66 and a 200 day moving average of $3.60. Universe Pharmaceuticals has a 12 month low of $2.00 and a 12 month high of $17.96. The company has a quick ratio of 3.90, a current ratio of 4.05 and a debt-to-equity ratio of 0.04.

Universe Pharmaceuticals (NASDAQ:UPC) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($1.38) earnings per share for the quarter. The company had revenue of $4.52 million for the quarter.

About Universe Pharmaceuticals

Universe Pharmaceuticals, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for ocular diseases. The company’s primary research efforts center on small-molecule compounds designed to address unmet needs in glaucoma, ocular hypertension and post-surgical ocular inflammation. By leveraging targeted enzyme inhibition and proprietary formulation technologies, Universe aims to bring forward topically administered medications that combine efficacy with an improved safety profile versus existing treatments.

The company’s lead candidate, UPC-1001, has been advanced into clinical trials for the treatment of open-angle glaucoma and ocular hypertension, where it seeks to lower intraocular pressure through a unique mechanism of action.